Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zalunfiban - Celecor Therapeutics

Next Previous
Drug Profile

Zalunfiban - Celecor Therapeutics

Alternative Names: RUC 4; RUC-4 acetate; Zalunfiban acetate - Celecor Therapeutics

Latest Information Update: 03 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rockefeller University
  • Developer CeleCor Therapeutics
  • Class Acetamides; Anti-ischaemics; Antiplatelets; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Small molecules; Thiadiazoles
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myocardial infarction
  • No development reported Coronary artery disease

Most Recent Events

  • 13 May 2025 CeleCor Therapeutics completes phase the III CELEBRATE trial in Myocardial infarction in Netherlands, Canada, Czech Republic, France, Hungary, Mexico, Romania, USA (SC) (NCT04825743)
  • 28 Jan 2023 No recent reports of development identified for preclinical development in Myocardial-infarction in USA (SC, Injection)
  • 28 Mar 2022 No recent reports of development identified for phase-I development in Coronary artery disease in USA (SC, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top